A recently published study found an association between PARP inhibitor (PARPi) treatment and an increased risk of hematological adverse events (AEs), including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer (mCRPC).1
The findings from this meta-analysis echo other studies evaluating hematologic AEs when using PARPis in additional cancer types.
The study, which consisted of a systematic review and meta-analysis of data from 8 phase 2 and 3 randomized clinical trials, linked PARPi use with an increased risk of all-grade anemia (risk ratio [RR], 3.37; 95% CI, 2.37-4.79; P =.00001), thrombocytopenia (RR, 4.54; 95% CI, 1.97-10.44; P =.0004), and neutropenia (RR, 3.11; 95% CI, 1.60-6.03; P =.0008). There were also increased risks observed for high-grade anemia (RR, 6.94; 95% CI, 4.06–11.86; P <.00001) and thrombocytopenia (RR, 5.52; 95% CI, 2.80–10.88; P <.00001).
“While PARPis have shown favorable clinical impacts on [prostate cancer] survival, they do come with adverse effects on bone marrow and often necessitate subsequent blood replacement therapies…Further, since PARPis are reserved for those with advanced disease, physicians must emphasize a balance between therapeutic benefit and potential effect of AEs on the patient’s quality of life. The primary strength of this study lies in its dedicated evaluation of hematological AEs in mCRPC, which may inform the above PARPi considerations,” study authors wrote in findings published in Cancers.
The 8 trials in mCRPC included in the meta-analysis were:
All 8 studies were evaluable for anemia AEs. The incidence of all-grade anemia in the PARPi cohorts was 48.7%, and the incidence of high-grade anemia was 24.9% Five studies could be evaluated for thrombocytopenia outcomes, and the incidences for all-grade and high-grade thrombocytopenia were 16.9% and 3.70%, respectively, in the PARPi cohorts. Four studies were evaluable for neutropenia outcomes and showed that all-grade neutropenia incidence was 18.14% and high-grade neutropenia incidence was 11.36%.
Niraparib demonstrated the lowest RR for all hematological AEs, with a RR for anemia of 2.27, thrombocytopenia of 2.49, and neutropenia of 0.008. The lowest RRs for anemia (2.44) and thrombocytopenia (2.49) were observed in combination with abiraterone.
All of the studies were published between 2017 and 2023. A collective 3904 patients were enrolled in these studies; 2218 were administered a PARPi and 1686 were administered a placebo or other cancer treatment. Across the patients who were treated with a PARPi, 15.1% (n = 323) discontinued treatment (not including NCI 9012) and 32.4% (n = 522) reduced their dose (not including NCI 9012 and KEYLYNK-010), due to an AE.
The findings from this meta-analysis echo other studies evaluating hematologic AEs when using PARPis in additional cancer types. A 2021 meta-analysis of PARPi use across multiple cancer types found an increased risk of all-grade anemia (RR, 2.32; 95% CI, 1.78-3.01; P <.0000), neutropenia (RR, 1.69; 95% CI, 1.38-2.07; P <.00001), and thrombocytopenia (RR, 2.54; 95% CI, 1.87-3.45; P <.00001) when PARPis were administered vs other cancer treatments.2 Further, the risk of high-grade hematological AEs was also significantly increased, and all 5 of the investigated PARPis were associated with a significant increased risk of anemia.
References
1. Bowling GC, Swargaloganathan P, Heintz C, et al. Hematological toxicities with PARP inhibitors in prostate cancer: A systematic review and meta-analysis of phase II/III randomized controlled trials. Cancers (Basel). 2023;15(19):4904. Published 2023 Oct 9. doi:10.3390/cancers15194904
2. Wang C, Li J. Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. J Clin Pharm Ther. 2021;46(3):571-584. doi:10.1111/jcpt.13349
Grant to fund research on biomarkers for toxicity from prostate cancer radiation
July 11th 2024“By understanding the mirSNP genetic markers that predispose patients to adverse side effects from cancer therapy we can tailor these therapies to minimize harm and maximize efficacy," says Joanne B. Weidhaas, MD, PhD, MS.
Gene-expression signature could serve as biomarker for recurrence in ccRCC
June 26th 2024“Even when we adjusted for other clinical variables, like age or grade of tumor, this signature was still independently associated with recurrence after treatment for this form of kidney cancer," says Simpa S. Salami, MD, MPH.